Reklama
twitter
youtube
facebook
instagram
linkedin
Reklama
Reklama

Sopharma AD: NWZ (11:00) - projekty uchwał: emisja warrantów i akcji (2023-04-21)

|
selectedselectedselected
Reklama
Aa
Udostępnij
facebook
twitter
linkedin
wykop

UNI-EN 20:Convening of a General meeting of warrant holders for June 2 2023

Firma: SOPHARMA AD
Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:
  1. SFW_GMW_02062023_EN.rar

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 20 / 2023
Date of issue: 2023-04-21
Short name of the issuer
SOPHARMA AD
Subject
Convening of a General meeting of warrant holders for June 2 2023
Official market - legal basis
art. 56. 1. 2 of Act on Public Offering.
Unofficial market - legal basis
Contents of the report:
The Board of Directors hereby convenes a General Meeting of the holders of warrants of “SOPHARMA” AD with the unique identification code SFAGMW02062023 to be held on 2 June 2023 at 14:00 hours (11:00 UTC) at the Company's headquarters in Sofia city with place of holding: 5 Lachezar Stanchev Str., Ground Floor, Sopharma Business Towers, Sopharma Event Center, and in the absence of a quorum on that date - on 23 June 2023 at the same location, with the same starting time and agenda.
The General Meeting of Warrant holders scheduled to be held on June 2, 2023 be held with the following agenda and with the following proposed resolutions by the Board of Directors:
Substantive issues:
1. Adoption of a Report on the movement of the price of ordinary shares of "SOPHARMA" AD on the regulated market, organized by the "Bulgarian Stock Exchange" AD, for the last 12 months; Draft decision: The general meeting of warrant holders accepts a Report on the movement of the price of ordinary shares of "SOPHARMA" AD on the regulated market, organized by the "Bulgarian Stock Exchange" AD, for the last 12 months;
2. Adopting a decision to exercise the warrants’ rights. Draft decision: The general meeting of the holders of warrants with ISIN BG9200001212 adopts a decision to exercise the rights to subscribe shares from a future increase in the capital of "SOPHARMA" AD, by issuing 44 925 943 number of ordinary, registered, dematerialized shares, with the right to vote, with a nominal value of BGN 1 each and an issue value of BGN 4.13 per share, provided that the shares from the increase are subscribed solely by the warrant holders;
3. Requesting that the Board of Directors adopts a decision on a conditional capital increase. Draft decision: Requesting that the Board of Directors adopts a decision on a capital increase under the provisions of the Company's Articles of Association, Art. 195 of the Commercial Code and in accordance with art. 113, para. 2, item 2 of the LPOS, in which the warrant holders can exercise their rights under item 2 of the agenda, and under the terms and conditions described in the Prospectus for the public offering of warrants, confirmed with a Decision of the Financial Supervision Commission № 804 – E/04.11.2021.
Annexes
File Description
SFW_GMW_02062023_EN.rar
SFW_GMW_02062023_EN.rar

SOPHARMA AD
(fullname of the issuer)
SOPHARMA AD Farmaceutyczny (far)
(short name of the issuer) (sector according to clasification
of the WSE in Warsow)
1220 Sofia
(post code) (city)
IlienskoShosse 16
(street) (number)
+359 2 813 42 00 +359 2 936 02 86
(phone number) (fax)
(e-mail) (web site)
nd
(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date Name Position / Function Signature
2023-04-21 Ognian Ivanov Donev Executive Director

Cena akcji Sopharma

Cena akcji Sopharma w momencie publikacji komunikatu to 13.6 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.

W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.

Jesteś dziennikarzem i szukasz pracy? Napisz do nas

Masz lekkie pióro? Interesujesz się gospodarką i finansami? Możliwe, że szukamy właśnie Ciebie.

Zgłoś swoją kandydaturę

Reklama